Fresenius Medical Care

2022 HospeTrack Hospital Intelligence Insights for Bahrain - Featuring Fresenius Medical Care, Drager, Philips Healthcare and Siemens Healthineers Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Health, Other Health, Universe, Hospital, Total, Dräger (company), Public, MRI, Degenerative disease, SPECT, Worksheet, Fresenius Medical Care, GPS, Siemens Healthineers, ORS, Growth, Size, COVID-19, CT, Kingdom, ICU, Incubator, Room, Non-communicable disease, Private sector, Teaching hospital, Philips, GE Healthcare, Critical care, Canon Medical Systems Corporation, Type, Hitachi, Cath lab, PET, Investment, Data, Physician, Microsoft Excel, Cardiology, Research, Google Images, Bed, GCC, Cryptocurrency, Healthcare, Health insurance, Medical imaging, Medical device, Toshiba

Key medical device companies featured in the dataset include: Fresenius Medical Care, Drager, Philips Healthcare, Siemens Healthineers, GE Healthcare, Toshiba (Canon Medical Systems), Hitachi, Mindray.

Key Points: 
  • Key medical device companies featured in the dataset include: Fresenius Medical Care, Drager, Philips Healthcare, Siemens Healthineers, GE Healthcare, Toshiba (Canon Medical Systems), Hitachi, Mindray.
  • HospeTrack Hospital Intelligence for Bahrain, Guidance & Hospital Segmentation
    Provides brief methodology of research along with extensive detail around total coverage of hospitals in Bahrain, by type of hospital.
  • HospeTrack Hospital Intelligence for Bahrain, Insight Summary
    3.4 IB Penetration Summary for Bahrain by Care Level of Hospital, 2022
    4.
  • HospeTrack Hospital Intelligence for Bahrain, IB Base File
    Provides the raw data for all installed base equipment by account in Bahrain.

ATI Physical Therapy Names Healthcare Partnerships Leader Scott Gregerson as Chief Growth Officer

Retrieved on: 
Thursday, December 22, 2022
Vitti, Family, Patient, ATI, CGO, NYSE, Fresenius Medical Care, Health, Negotiation, University, Growth, Marketing, MSK, Workplace, University of California, San Francisco, ATI Physical Therapy, Sonoma Valley Hospital, Washington and Lee University School of Law, Calendar, Management, Medicine, Gregerson

BOLINGBROOK, Ill., Dec. 22, 2022 /PRNewswire/ -- ATI Physical Therapy, Inc. ("ATI" or the "Company") (NYSE: ATIP), the largest single-branded outpatient physical therapy provider in the United States, today announced that Scott Gregerson will join ATI as its new Chief Growth Officer beginning Jan. 3.

Key Points: 
  • BOLINGBROOK, Ill., Dec. 22, 2022 /PRNewswire/ -- ATI Physical Therapy, Inc. ("ATI" or the "Company") (NYSE: ATIP), the largest single-branded outpatient physical therapy provider in the United States, today announced that Scott Gregerson will join ATI as its new Chief Growth Officer beginning Jan. 3.
  • Gregerson brings two decades of experience as a healthcare executive to ATI, including several roles leading business development and strategic partnerships for large care systems.
  • "When we look at the future of growth at ATI, continuing to partner and innovate across the healthcare landscape will be an essential component of our success," said ATI Chief Executive Officer Sharon Vitti.
  • Over the last decade, Gregerson has held executive leadership positions at Envison Healthcare, Epic Care, Stanford Healthcare and ValleyCare Health.

DaVita's Move It with Purpose Event Raises Funds for Bridge of Life

Retrieved on: 
Tuesday, December 20, 2022
AmerisourceBergen, Quality of life, PD, The Bridge: The Life and Rise of Barack Obama, Wilmer Cutler Pickering Hale and Dorr, Family, Patient, Education, NYSE, Dialysis, NxStage, Community, Fresenius Medical Care, Transplant, Chronic kidney disease, Wells Fargo, Kidney disease, Gary Doer, Kidney, Diabetes, BOL, Philippine Council of Evangelical Churches, Friends, DaVita Inc., Gardening, Medical missions, Therapy, DVA, Peritoneal dialysis, Hypertension, World Wide Technology, Baxter, Physician, Conditional sentence, Yoga, Pharmaceutical industry, Health insurance, Medicine

DENVER, Dec. 20, 2022 /PRNewswire/ -- Today, DaVita announced that over 4,400 DaVita teammates, friends, family and key members of the kidney care community joined together to participate in the inaugural Move It with Purpose (MIWP) event to benefit Bridge of Life, a nonprofit founded by DaVita to support the prevention and treatment of chronic disease.

Key Points: 
  • The event has raised nearly $15 million for the nonprofit since 2007, enabling Bridge of Life to enhance kidney care globally through its medical missions.
  • "Bridge of Life is thrilled to be the recipient of so much generosity and goodwill thanks to DaVita, event sponsors and participants," said Lori Vaclavik, executive director for Bridge of Life.
  • For every mile logged on the MIWP site, DaVita donated $1 to Bridge of Life, up to $250,000.
  • Bridge of Life has assisted more than 130,000 people in underserved communities since its first mission in 2006.

2008® Series Hemodialysis Machine with New Tubing Released for Care Delivery

Retrieved on: 
Monday, December 19, 2022
Dialysis, Platinum, Series, Chronic kidney disease, Food, FDA, Sale, All rights reserved, Regulation of tobacco by the U.S. Food and Drug Administration, NDL, Ultrafiltration, Trust, Multimedia, Kagan, PCBA, Blue star, Plasma, Medical information, Senior, Fresenius Medical Care, Patient, SLED, Pharmaceutical industry, Medical device

WALTHAM, Mass., Dec. 19, 2022 /PRNewswire/ -- Fresenius Medical Care North America's (FMCNA) Renal Therapies Group, a leading provider of products and services for people with chronic kidney failure, announced that the U.S. Food and Drug Administration (FDA) has cleared the 2008 Series hemodialysis machine with platinum catalyst silicone tubing.

Key Points: 
  • The modified tubing is another example of our commitment to helping our customers provide the highest quality of care to their patients possible.
  • All new 2008T hemodialysis machines shipped since October 27, 2022, use platinum catalyst tubing.
  • 2008T BlueStar™ Hemodialysis Machine: The 2008T BlueStar Hemodialysis Machine is indicated for acute and chronic dialysis therapy in a healthcare facility.
  • Fresenius Medical Care, the triangle logo, 2008, and 2008T BlueStar are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies.

EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care

Retrieved on: 
Sunday, December 18, 2022
FMS, Dialysis, Laboratory, Takeda Pharmaceutical Company, FME, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, SE, CFO, Northwestern University, Knowledge, Critical care, News, Frankfurt Stock Exchange, Supervisory board, Kidney, Growth, Abbott Laboratories, Business administration, Master of Business Administration, Kellogg School, Fresenius Medical Care, TAP Pharmaceuticals, COVID-19, Patient, EVP, Transformer, Health insurance, Security (finance), Pharmaceutical industry, Management

EQS-News: Fresenius Medical Care AG & Co. KGaA

Key Points: 
  • EQS-News: Fresenius Medical Care AG & Co. KGaA
    Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care
    The issuer is solely responsible for the content of this announcement.
  • Helen Giza (54) has been appointed Chief Executive Officer of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, with immediate effect.
  • Helen Giza will continue to serve as Chief Financial Officer of Fresenius Medical Care until a successor is appointed for this position.
  • In her capacity as CEO of Fresenius Medical Care, Ms. Helen Giza will also be a member of the Management Board of Fresenius Management SE.

American Oncology Network Appoints New Chief Development Officer

Retrieved on: 
Wednesday, December 7, 2022
Physician, Practitioner, Wharton School of the University of Pennsylvania, Society for Healthcare Strategy and Market Development, LifePoint Health, Economics, Concentra, Belott, Texas, Knowledge, AON, University, Growth, MBA, Pathology, Senior, Fresenius Medical Care, Johann Joseph von Prechtl, Patient, Business development, Hospital, Management, Medicine

FORT MYERS, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) , a high-growth medical oncology provider with a focus on supporting the long-term viability of community-based cancer care and treatments, announced today the appointment of Anthony Belott as AON’s new Chief Development Officer.

Key Points: 
  • FORT MYERS, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) , a high-growth medical oncology provider with a focus on supporting the long-term viability of community-based cancer care and treatments, announced today the appointment of Anthony Belott as AON’s new Chief Development Officer.
  • Belott will succeed current President and Chief Development Officer Brad Prechtl, who will retire effective January 1, 2023.
  • Prechtl will continue to serve as a special advisor to the network and its board after the new year.
  • Belott joins AON after serving as LifePoint Health’s Vice President of In-Market Development.

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, CSL, Probability, Commercial Court (England and Wales), Dialysis, Nephrology, ASX, Patient, ART, Commercial Court, Accounting, Element, LR, Fresenius Medical Care, SIX Swiss Exchange, Commerce, Marketing, Risk, Vifor Pharma

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma AG ("Vifor") announced today that the Commercial Court St.Gallen has cancelled (kraftlos erklrt) all remaining publicly held registered shares of Vifor with a nominal value of CHF0.01 each (each a "Vifor Share").
  • Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:
    As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD179.25 in cash per cancelled Vifor Share.
  • The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.
  • Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

Row Associates Celebrates Inaugural Event, Announces Healthcare rpm23 at the Renowned Country Music Hall of Fame and Museum®

Retrieved on: 
Thursday, December 8, 2022
Country song, Music, Science, Nashville Songwriters Hall of Fame, General Atlantic, Country Music Hall of Fame and Museum, Virginia Scholastic Rowing Association, Daniel T. McCarty, Entrepreneurship, FACP, Fresenius Medical Care, River, Health, Marketing, Senior, Round, CMA, ASCAP, MD, Environment, Medidata Solutions, Partner (business rank), General Electric, Infusion, Former, FINRA, Doctor of Philosophy, McKesson Corporation, Songwriter, Medicare, Organization, Medical device, Management, Hospital, Health care

Row Associates is also pleased to announce details regarding Healthcare rpm23 following its inaugural event earlier this year:

Key Points: 
  • Row Associates is also pleased to announce details regarding Healthcare rpm23 following its inaugural event earlier this year:
    The inaugural Healthcare rpm event held in October 2022 assembled substantial communities of executive leadership to discuss opportunities, evaluate challenges and share perspectives surrounding important sub-sectors of the healthcare ecosystem.
  • Rivers Rutherford was joined by celebrated country music songwriters Tim James and Bob DePiero.
  • Row Associates LLC is registered as a Capital Acquisition Broker with the U.S. Securities and Exchange Commission and is a member of FINRA andSIPC.
  • Background information regarding Row Associates' registered representatives may be researched via FINRA's BrokerCheck System.

Dialysis Services Market Revenue to Reach USD 87 Billion by 2027. The Market to Offer USD 12 Billion Opportunities in the Next 5 Years - Arizton

Retrieved on: 
Wednesday, December 7, 2022
Dialysis, Fresenius, ADMS, DaVita Inc., Northwest Kidney Centers, Patient, The Rogosin Institute, Fresenius Medical Care, ARC, COVID-19, Growth, Organization, Acquisition, Health insurance

https://www.arizton.com/request-sample/3582

Key Points: 
  • https://www.arizton.com/request-sample/3582
    Due to the growing demand for healthcare services, there has been a significant shift towards ambulatory and mobile care.
  • In India, the NephroPlus company started the dialysis on wheels initiative in dialysis care.
  • In the US, Odulair LLC is one of the well-known mobile dialysis service provider organizations that deliver several dialysis services annually in the US.
  • It is a mobile medical manufacturer pioneer in building commercial mobile dialysis units in the US and international market.

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

Retrieved on: 
Monday, November 28, 2022
Health, Fitness & Nutrition, General Health, Pharmaceutical, Cardiology, Biotechnology, Marketing, CSL, Degenerative disease, Heart, Dizziness, Anemia, Diagnosis, Conditional sentence, Multimedia, Systematic review, Iron deficiency, Dialysis, Risk, NHC, Pica, Patient, PBM, Life, Iron, Clay, ASX, Face, Nutritional anemia, Fatigue, URL, World Health Organization, Australian Longitudinal Study on Women's Health, Disease, Common, Transfusion medicine, National Medical Products Administration, Veni, vidi, vici, BMC, NRDL, Collection, PLOS, Fresenius Medical Care, B, Woman, NMPA, Infection, Safety, Nephrology, Fresenius (company), Pharmaceutical industry, Health insurance, Dietary supplement, Hospital, Silviculture

View the full release here: https://www.businesswire.com/news/home/20221127005020/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
    CSL Vifor and Fresenius Kabi today announced that Chinas National Medical Products Administration (NMPA) has approved Ferinject, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly.
  • We are thrilled about the marketing authorization of Ferinject, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia, said Herv Gisserot, General Manager of CSL Vifor.
  • There is a high unmet need in China, which has the worlds largest iron deficiency population, and we are confident that Ferinject can make a meaningful difference in the treatment of these patients.
  • This open label, randomized multicenter study showed that Ferinject is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.